QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.107.019299v1 36/3/508    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kao, T.-T. Articles by Fu, T.-F. Search for Related Content PubMed PubMed Citation Articles by Kao, T.-T. Articles by Fu, T.-F.

Characterization and Comparative Studies of Zebrafish and Human Recombinant Dihydrofolate Reductases—Inhibition by Folic Acid and Polyphenols

Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan (T.-T.K., K.-C.W., W.-N.C., C.-Y.L., T.-F.F.); Faculty of Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan (B.-H.C.); Department of Biochemistry and Molecular Biology, College of Medicine and Cardiovascular Research Center, National Cheng Kung University, Tainan, Taiwan (H.-L.W., G.-Y.S.); School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan (J.N.T.)

Dihydrofolate reductase (DHFR) catalyzes folic acid reduction and recycles dihydrofolate generated during dTMP biosynthesis to tetrahydrofolate. DHFR is the main target of methotrexate, the most widely used agent for antifolate therapy. Nevertheless, the emergence of methotrexate-resistance has greatly impeded the curative potential of this drug. Therefore, drugs with improved efficacy are still in demand, as well as an efficient in vitro assay system and animal model for antifolate drug discovery. The aim of this study is to evaluate the suitability of using zebrafish DHFR as an alternative assay system for antifolate drug discovery. The cDNAs encoding zebrafish and human DHFR were cloned, overexpressed, and purified. Similar structural and kinetic properties were revealed between zebrafish and human recombinant DHFRs. The susceptibilities of both enzymes to known DHFR inhibitors, including methotrexate and trimethoprim, and compounds with antifolate potential, such as polyphenols, are also comparable. In addition, the DHFR-mediated dihydrofolate reduction was significantly inhibited by its own substrate folic acid. An unexpected tissue-specific distribution of DHFR was observed with the highest level present in ova and brains of zebrafish. DHFR is also abundant in zebrafish embryos of early stages and decreased abruptly after 3 days postfertilization. The substantial resemblance between zebrafish and human DHFRs, as demonstrated in this study, provides compelling evidence supporting the use of zebrafish DHFR as an in vitro assay system for folate-related studies and drug discovery.

This article has been cited by other articles:

				T.-T. Kao, W.-N. Chang, H.-L. Wu, G.-Y. Shi, and T.-F. Fu Recombinant Zebrafish {gamma}-Glutamyl Hydrolase Exhibits Properties and Catalytic Activities Comparable with Those of Mammalian Enzyme Drug Metab. Dispos., February 1, 2009; 37(2): 302 - 309. [Abstract] [Full Text] [PDF]

				S. Sun, Y. Gui, Y. Wang, L. Qian, X. Liu, Q. Jiang, and H. Song Effects of methotrexate on the developments of heart and vessel in zebrafish Acta Biochim Biophys Sin, January 1, 2009; 41(1): 86 - 96. [Abstract] [Full Text] [PDF]